Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 5 uppsatser.

Little is known about potential influences of kinase pathway modulation on expression and activity of P-glycoprotein (P-gp). A protein kinase inhibitor (PKI) library was screened, to determine its effects on activity and expression of P-gp, in various cell lines. Cell lines were incubated with PKI for 24 h. Subsequent P-gp substrate accumulation studies were performed. Changes in P-gp activity and/or expression ≥ 25% compared to control were considered hits. Kinase pathways identified as P-gp activity hits were examined for their ability to modulate permeability. PKI families GSK-3, Craf1 and VEGFR2 and Tie-2, significantly modulated P-gp activity in the MDCK cell line. PKI families GSK-3, Iκκ and Jnk2/3 significantly modulated P-gp activity in the Caco-2 cell line. Few P-gp activity hits significantly modulated P-gp expression. PKIs modulate P-gp activity more than P-gp expression in a cell line dependent manner, excluding GSK-3 PKI family, which appears to be cell line independent.

Licentiatavhandling (sammanfattning) Linköping : Linköpings universitet, 2009. / Härtill 2 uppsatser.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2009. / Härtill 5 uppsatser.

<p>Protein kinases are enzymes that catalyse the phosphoryl transfer from the g-phosphate of ATP to acceptor amino acids in proteins. The specificity of selected model protein kinases was studied at three different levels using a) novel bi-substrate-analogue inhibitors, b) synthetic peptide substrates and c) mutated protein substrate analogues. </p><p>A new class of protein kinase bi-substrate-analogue inhibitors was designed on the basis of adenosine-5’-carboxylic acid derivatives, where a short arginine containing peptide was attached to the 5'-carbon atom of the adenosine sugar moiety via a linker chain. These compounds showed high inhibitory potential against two basophilic protein kinases, the protein kinase A (PKA) and protein kinase C (PKC), with IC50 values in the nanomolar range, but no inhibitory activity towards the acidophilic kinases CK1 and CK2. The inhibitors were efficiently applied for affinity purification of PKA using MgATP as well as L-arginine as eluting agents. </p><p>Ca2+-dependent protein kinase (CDPK-1) was purified from maize seedlings and its substrate specificity was studied using a set of synthetic peptides. These were derived from the phosphorylatable sequence RVLSRLHS(15)VRER of maize sucrose synthase 2 (SuSy2), and a consensus sequence motif A/LXRXXSXRZR (where X denotes a position with no strict amino acid requirements and Z a position strictly not tolerating arginine) was defined from a study using arrays of systematically varied peptides attached to cellulose membrane (SPOTs^TM membranes). The SuSy2 derived peptides were also found to be efficient substrates for mammalian PKC, but showed low reactivity in the case of PKA. On the basis of this peptide motif, a positionally oriented peptide library approach based on ESI-MS detection of phosphopeptides in initial velocity conditions was designed for quantitative kinetic characterization of protein kinase specificity profiles. On the basis of the obtained data an optimal peptide substrate for PKC, FRRRRSFRRR, was designed. </p><p>The specificity of protein kinase A was studied using site-directed mutagenesis in the phosphorylation site of L-type pyruvate kinase (L-PK), and comparison of the obtained data with the data from previous studies on structurally altered peptide substrates revealed that amino acid alterations in short peptide substrates cause stronger effects on the phosphorylation rate than the corresponding alterations in the protein substrate L-PK.</p>

Protein kinases are enzymes that catalyse the phosphoryl transfer from the g-phosphate of ATP to acceptor amino acids in proteins. The specificity of selected model protein kinases was studied at three different levels using a) novel bi-substrate-analogue inhibitors, b) synthetic peptide substrates and c) mutated protein substrate analogues. A new class of protein kinase bi-substrate-analogue inhibitors was designed on the basis of adenosine-5’-carboxylic acid derivatives, where a short arginine containing peptide was attached to the 5'-carbon atom of the adenosine sugar moiety via a linker chain. These compounds showed high inhibitory potential against two basophilic protein kinases, the protein kinase A (PKA) and protein kinase C (PKC), with IC50 values in the nanomolar range, but no inhibitory activity towards the acidophilic kinases CK1 and CK2. The inhibitors were efficiently applied for affinity purification of PKA using MgATP as well as L-arginine as eluting agents. Ca2+-dependent protein kinase (CDPK-1) was purified from maize seedlings and its substrate specificity was studied using a set of synthetic peptides. These were derived from the phosphorylatable sequence RVLSRLHS(15)VRER of maize sucrose synthase 2 (SuSy2), and a consensus sequence motif A/LXRXXSXRZR (where X denotes a position with no strict amino acid requirements and Z a position strictly not tolerating arginine) was defined from a study using arrays of systematically varied peptides attached to cellulose membrane (SPOTsTM membranes). The SuSy2 derived peptides were also found to be efficient substrates for mammalian PKC, but showed low reactivity in the case of PKA. On the basis of this peptide motif, a positionally oriented peptide library approach based on ESI-MS detection of phosphopeptides in initial velocity conditions was designed for quantitative kinetic characterization of protein kinase specificity profiles. On the basis of the obtained data an optimal peptide substrate for PKC, FRRRRSFRRR, was designed. The specificity of protein kinase A was studied using site-directed mutagenesis in the phosphorylation site of L-type pyruvate kinase (L-PK), and comparison of the obtained data with the data from previous studies on structurally altered peptide substrates revealed that amino acid alterations in short peptide substrates cause stronger effects on the phosphorylation rate than the corresponding alterations in the protein substrate L-PK.

Thesis (Ph. D.)--University of Missouri-Columbia, 2007. / The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Vita. "August 2007" Includes bibliographical references.

<p>Protein kinases are essential in cell signaling pathways and are well-validated targets for cancer therapeutics and detection of activity levels. Yet, there remains a critical need for kinase inhibitors with high specificity and potency. The development of DNA-encoded library (DEL) technology dramatically facilitates the discovery of ligands to therapeutically relevant proteins. The preparation of combinatorial libraries followed by stringent selections can be exploited to rapidly generate hit molecules that bind to a large variety of targets.</p> <p>A combinatorial library of peptidomimetics is prepared and subjected to a selection for enriching molecules that can serve as substrates for tyrosine kinase Src. Non-natural substrate molecules are recognized by the anti-phosphotyrosine antibody during the selection. Using biophysical characterization assays including ADP-Glo and NMR, the resulting hits are investigated as novel peptide-substrate competitive inhibitors, as well as specific chemical probes that would benefit kinase activity detection. An ester derivative of the lead compound SrcDEL10 demonstrates cellular activity with inhibition of Src-dependent signaling in cell culture. Subsequently, our effort extends to parallel selections with a highly diverse-scaffold DEL on three cancer-related tyrosine kinases. Several hit molecules are validated with differential phosphotransfer activities among Src, Lyn, and Syk. Studies on the structure activity relationship of hit molecules produce selective kinase substrates with the lowest molecular weights reported to date. Potential bisubstrate inhibitors, showing above 8-fold Src selectivity over Lyn, are designed based on structures of selective substrates.</p> <p>Meanwhile, high sensitivity of DNA sequence analysis enables the development of specific and multiplexed activity assays. Using the substrate selection strategy, we develop a DNA-based kinome activity profiling assay using DNA conjugates of tyrosine kinase peptide substrates. Selective enrichment of phosphorylated probes enables activity detection by either quantitative PCR (qPCR) or parallel DNA sequencing. Results with detecting recombinant kinases demonstrated a low (~50 pM kinase) limit of detection. A library of 96 DNA-substrate conjugates enabled multiplexed tyrosine kinase assays in cell lysates in a manner analogous to peptide microarrays. This DNA-based assay potentially empowers the detection of tumor biomarkers with high specificity, lower detection limit, multiplexing capability, and high cost-effectiveness.</p> <p>Together, this research uses DNA-based technologies to assist developing new therapeutics and diagnostics, drug target validation, unveiling drug mechanisms of action, and understanding the role of protein phosphorylation in disease progression.</p>

Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Adéla Janoušková Supervisor: RNDr. Jakub Hofman, Ph.D. Title of diploma thesis: Study on impact of selected protein kinase inhibitors on drug resistance mediated by cytochromes P450 Pharmacokinetic drug resistance often leads to failure of an anticancer therapy. One of the mechanisms is increased efflux of drugs from tumour cells, whereas some studies suggest that increased drug conversion to an inactive metabolite might be another contributing mechanism. The aim of this work was to define the possible role of CYP3A4 and CYP2C8 enzymes in the phenomenon of pharmacokinetic resistance and to investigate the possibility of its modulation by new targeted drugs. In the first part, we used the MTT proliferation method together with HepG2 cells stably transduced with particular human enzymes and demonstrated significant involvement of CYP3A4 in docetaxel resistance. In the following part, we examined the inhibitory effects of four selected tyrosine kinase inhibitors on the CYP3A4 activity in intact cells using a commercial kit. Cobimetinib and dabrafenib showed significant inhibitory activity, while osimertinib and brivanib did not. In the final part, we demonstrated the ability of the first two...

Τα φυσικά προϊόντα αποτελούν σημαντική πηγή βιοδραστικών ενώσεων με ποικίλο φαρμακολογικό ενδιαφέρον. Παρά την τεράστια πρόοδο που έχει συντελεστεί στη χημική σύνθεση φαρμάκων, ακόμα και σήμερα το ¼ των φαρμάκων που διατίθεται στην αγορά προέρχεται από φυσικές πηγές. Η σύγχρονη ανακάλυψη φαρμάκων βασίζεται πλέον στην εστιασμένη δράση ενώσεων έναντι συγκεκριμένων μοριακών στόχων που εμπλέκονται στην εμφάνιση και εξέλιξη της κάθε νόσου. Μοριακοί στόχοι με ιδιαίτερο ενδιαφέρον είναι και οι κυκλινο-εξαρτώμενες κινάσες (CDKs). Οι CDKs είναι μια κατηγορία πρωτεϊνικών κινασών οι οποίες μεταξύ άλλων διαδραματίζουν καθοριστικό ρόλο στη ρύθμιση και ομαλή εξέλιξη του κυτταρικού κύκλου, διασφαλίζοντας τον φυσιολογικό πολλαπλασιασμό των κυττάρων. Η απορρύθμιση της λειτουργίας τους έχει ως επακόλουθο την εμφάνιση διαφόρων παθολογικών καταστάσεων μεταξύ των οποίων και διαφόρων καρκινικών όγκων. Μέχρι σήμερα πληθώρα φυσικών και συνθετικών ενώσεων έχουν εμφανίσει ανασταλτική δράση έναντι των CDKs και αρκετές από αυτές βρίσκονται σε προχωρημένα στάδια κλινικών δοκιμών. Πρόσφατα πειραματικά δεδομένα έδειξαν ότι η CDK1, ελλείψει των υπολοίπων CDKs της μεσόφασης (2, 4, 6), επαρκεί για την ομαλή ολοκλήρωση του κυτταρικού κύκλου. Τα αποτελέσματα αυτά έγιναν αφορμή ώστε πολλές ερευνητικές προσπάθειες να στραφούν και προς την ανάπτυξη ενώσεων με εκλεκτική δράση έναντι της CDK1. Σκοπός της παρούσας μελέτης είναι ο σχεδιασμός και η σύνθεση νέων μικρών ετεροκυκλικών μορίων με πιθανή ανασταλτική δράση έναντι του ενζύμου CDK1. Συγκεκριμένα, σχεδιάσθηκαν νέα παράγωγα που θα έφεραν δύο νέους ισομερείς τετρακυκλικούς ινδολοαζεπινικούς σκελετούς. Ο σχεδιασμός των ενώσεων αυτών βασίστηκε σε δομικά χαρακτηριστικά φυσικών ή συνθετικών ενώσεων που έχουν μελετηθεί και έχουν εμφανίσει ανασταλτική δράση έναντι τόσο της CDK1 όσο και άλλων CDKs. Βασικό δομικό χαρακτηριστικό των τελικών μορίων, που έχει αποδειχθεί κρίσιμο για την εκδήλωση CDK ανασταλτικής δράσης σε συγγενείς ενώσεις, είναι ένας επταμελής λακταμικός δακτύλιος ο οποίος συμπυκνώνεται σε κατάλληλες θέσεις με έναν ινδολικό και έναν πυρρολικό δακτύλιο. Η υποκατάσταση του πυρρολικού δακτυλίου με μία καρβοξυαιθυλ-ομάδα στη θέση-2, σε συνδυασμό με την εισαγωγή κατάλληλων υποκαταστατών στον ινδολικό δακτύλιο, δύναται να οδηγήσει σε βιβλιοθήκες αναλόγων. Η προσέγγιση που ακολουθήθηκε για την σύνθεση των τελικών μορίων περιελάμβανε αμιδική σύζευξη κατάλληλων ινδολικών και πυρρολικών πρόδρομων ενώσεων και Pd-καταλυόμενη ενδομοριακή κυκλοποίηση (σύζευξη Heck) για τον σχηματισμό του βασικού τετρακυκλικού ινδολοαζεπινικού σκελετού. Στα πλαίσια της μελέτης, αρχικά μελετήθηκε η συνθετική πορεία παραλαβής αναλόγων ενός εκ των δύο αρχικά σχεδιασθέντων σκελετών. Η διερεύνηση και βελτιστοποίηση των ενδιάμεσων συνθετικών σταδίων οδήγησε στην σύνθεση 59 νέων ενδιάμεσων μορίων και 4 νέων τετρακυκλικών ινδολοαζεπινονικών τελικών προϊόντων. Τα τελικά προϊόντα έφεραν προστατευμένα τόσο το άζωτο του ινδολίου όσο και του πυρρολίου με την ίδια προστατευτική ομάδα, ενώ η προσπάθεια παραλαβής αναλόγων του μη προστατευμένου σκελετού δεν ήταν επιτυχής. Τέλος, η διερεύνηση της συνθετικής πορείας που θα απέδιδε ανάλογα του δεύτερου σκελετού δεν απέδωσε τα αναμενόμενα αποτελέσματα. / Natural products constitute an important source of bioactive compounds with a pharmacological interest. 25% of the drugs that are nowadays available in the market come from natural sources, despite the great progress in the field of chemical composition. Drugs’ development is currently based upon the focused action of certain compounds towards a specific molecular target which is involved in the appearance and evolution of each disease. Some such molecular targets of particular interest are the Cyclin-dependent kinases (CDKs). CDKs are a subfamily of protein kinases that regulate a number of cellular processes, including the cell cycle, ensuring the normality of cell division. The deregulation of their function leads to several diseases, including human tumour. To this day a large number of natural and chemical compounds have been characterized as CDK inhibitors and some of them are already in the late phases of clinical trials. Recent genetic studies have indicated that CDK1 is sufficient to drive the cell cycle in absence of other CDKs (2, 4, 6). These results have led researchers to develop compounds with selective inhibitory activity against CDK1. The current research aims at the development of new compounds with possible inhibitory activity against CDK1. The scientific process was more specifically based on the design and synthesis of new small heterocyclic, tetracyclic indoloazepino compounds. The design of the above compounds was based on structural features that exist in other already known natural or chemical CDK inhibitors. The biological results of similar compounds have indicated that the seven-member lactamic ring of structure has an important role in the inhibitory CDK activity. The basic structural component of the designed compounds, proven to be crucial for the manifestation of the CDK inhibitory function, is a seven member lactamic ring among a pyrrole and indole nuclei. The substitution of the pyrrole with a 2-ethyl-carboxylic substitute along with the introduction of substitutes on specific positions of the indole nuclei are expected to lead to the development of library compounds. The selected procedure includes amide coupling between specific indole and pyrrole compounds and finally C-C intermolecular coupling with Heck reaction. The final aim is to form the basic tetracyclic indoloazepino structure. The current research was primarily directed to the synthesis of one of the two already designed structures. The intermediate reactions of the above structure’s synthetic process were examined and optimized, leading to the isolation of 60 intermediate compounds and 4 new tetracyclic indoloazepino derivatives. In the final derivatives, the pyrrole and indole nitrogen appeared to be protected under the same protective group while an effort to remove these protective groups, through certain reactions, was unsuccessful. Finally, a research into a synthetic process that would provide corresponding derivatives with the second main structure, did not yield the expected results.